Asensus Surgical Stock Forecast, Price & News

-0.13 (-6.91 %)
(As of 04/16/2021 04:00 PM ET)
Today's Range
Now: $1.75
50-Day Range N/A
52-Week Range
Now: $1.75
Volume12.47 million shs
Average Volume30.81 million shs
Market Capitalization$407.03 million
P/E RatioN/A
Dividend YieldN/A
Asensus Surgical, Inc. engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery. It digitizes the interface between the surgeon and the patient to improve minimally invasive surgery through a new category of care called Digital Laparoscopy. The company's digital interface enables the use of capabilities, such as augmented intelligence, connectivity, and robotics in laparoscopy, as well as allows to address the current clinical, cognitive, and economic shortcomings in surgery. The company's products include Senhance Surgical System, a multi-port robotic surgery system that allows multiple robotic arms to control instruments and a camera; and SurgiBot System, a single-port system robotically enhanced laparoscopic surgical platform. It offers its products directly and through distributors in Europe, the United States, Japan, Taiwan, and internationally. The company was formerly known as TransEnterix, Inc. and changed its name to Asensus Surgical, Inc. in February 2021. Asensus Surgical, Inc. was founded in 2006 and is based in Morrisville, North Carolina.

Industry, Sector and Symbol

Industry Medical Devices
Phone919 765 8400
Year FoundedN/A



Sales & Book Value

Annual SalesN/A



Market Cap$407.03 million
Next Earnings Date5/13/2021 (Estimated)


Asensus Surgical (NYSE:ASXC) Shares Down 11.9%
April 12, 2021 |  americanbankingnews.com
Asensus Surgical (NYSE:ASXC) Trading Down 5.9%
April 6, 2021 |  americanbankingnews.com
Asensus Surgical (NYSE:ASXC) Stock Price Down 7.1%
March 29, 2021 |  americanbankingnews.com
Asensus Surgical (NYSE:ASXC) Shares Up 5.8%
March 25, 2021 |  americanbankingnews.com
See More Headlines


Overall MarketRank

0.00 out of 5 stars

Medical Sector

1859th out of 2,025 stocks

Medical Devices Industry

28th out of 30 stocks

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
-0.13 (-6.91 %)
(As of 04/16/2021 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ASXC News and Ratings via Email

Sign-up to receive the latest news and ratings for ASXC and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Asensus Surgical (NYSE:ASXC) Frequently Asked Questions

Is Asensus Surgical a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Asensus Surgical in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" Asensus Surgical stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ASXC, but not buy additional shares or sell existing shares.
View analyst ratings for Asensus Surgical
or view top-rated stocks.

What stocks does MarketBeat like better than Asensus Surgical?

Wall Street analysts have given Asensus Surgical a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Asensus Surgical wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Asensus Surgical's next earnings date?

Asensus Surgical is scheduled to release its next quarterly earnings announcement on Thursday, May 13th 2021.
View our earnings forecast for Asensus Surgical

How were Asensus Surgical's earnings last quarter?

Asensus Surgical, Inc. (NYSE:ASXC) released its quarterly earnings results on Wednesday, March, 10th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.11) by $0.02.
View Asensus Surgical's earnings history

Who are Asensus Surgical's key executives?

Asensus Surgical's management team includes the following people:
  • Mr. Anthony Fernando, Pres, CEO & Director (Age 49, Pay $391.88k)
  • Mr. Todd M. Pope, Sr. Advisor (Age 56, Pay $552.43k)
  • Mr. Shameze Rampertab B.Sc. MBA, CA, CPA, Exec. VP & CFO (Age 54)
  • Mr. Joshua B. Weingard, Chief Legal Officer & Sec. (Age 48)
  • Mr. Paul Ziegler, VP of Sales
  • Ms. Amanda Owens, Global Head of People
  • Dr. Stephanie M. Fitts, VP of Clinical, Quality and Regulatory Affairs (Age 55)

Who are some of Asensus Surgical's key competitors?

What is Asensus Surgical's stock symbol?

Asensus Surgical trades on the New York Stock Exchange (NYSE) under the ticker symbol "ASXC."

Who are Asensus Surgical's major shareholders?

Asensus Surgical's stock is owned by a number of retail and institutional investors. Top institutional investors include Enterprise Bank & Trust Co (0.03%).

Which major investors are buying Asensus Surgical stock?

ASXC stock was bought by a variety of institutional investors in the last quarter, including Enterprise Bank & Trust Co.

How do I buy shares of Asensus Surgical?

Shares of ASXC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Asensus Surgical's stock price today?

One share of ASXC stock can currently be purchased for approximately $1.75.

How much money does Asensus Surgical make?

Asensus Surgical has a market capitalization of $407.03 million.

How many employees does Asensus Surgical have?

Asensus Surgical employs 160 workers across the globe.

What is Asensus Surgical's official website?

The official website for Asensus Surgical is www.asensus.com.

How can I contact Asensus Surgical?

The company can be reached via phone at 919 765 8400.

This page was last updated on 4/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.